Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

715
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
715
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

2.0K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.0K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.9K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.9K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

744
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
744

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis.

ESMO real world data and digital oncology·2026
Same author

Effect of Advanced Pneumatic Compression Devices in the Treatment of Lymphedema: A Systematic Review and Meta-Analyses.

Lymphology·2025
Same author

Introduction and accuracy assessment of Nicolab's StrokeViewer in a developing stroke thrombectomy UK service. a service development/improvement project.

Clinical radiology·2024
Same author

Sensory Processing Assessment and Feedback in the Treatment of Complex Developmental Trauma.

Journal of child & adolescent trauma·2024
Same author

Correction: Validation of actigraphy sleep metrics in children aged 8 to 16 years: considerations for device type, placement and algorithms.

The international journal of behavioral nutrition and physical activity·2024
Same author

Initial experience using middle meningeal artery embolisation for patients with recurrent and high-recurrence-risk chronic subdural haematoma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2024
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Related Experiment Video

Updated: Mar 27, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K

Pimavanserin.

N S Hunter1, K C Anderson1, A Cox2

  • 1Department of Pharmaceutical Sciences, Sullivan University School of Pharmacy, Louisville, Kentucky, USA.

Drugs of Today (Barcelona, Spain : 1998)
|January 9, 2016
PubMed
Summary
This summary is machine-generated.

Pimavanserin effectively treats Parkinson's disease psychosis (PDP) symptoms like hallucinations and delusions. This novel medication offers a safe option for PDP patients, without worsening motor function, addressing a critical unmet need.

Keywords:
ACP-103Parkinson's disease psychosisPimavanserin

More Related Videos

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

3.8K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.6K

Related Experiment Videos

Last Updated: Mar 27, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K
Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry CIS-FSCV to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

3.8K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.6K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Parkinson's disease psychosis (PDP) lacks FDA-approved treatments.
  • Existing antipsychotics risk worsening motor function and carry mortality warnings in elderly patients.
  • Pimavanserin (ACP-103) is a selective 5-HT2A receptor inverse agonist.

Purpose of the Study:

  • To review the literature on pimavanserin for treating Parkinson's disease psychosis.
  • To evaluate pimavanserin's safety and efficacy in PDP patients.

Main Methods:

  • Review of Phase II and III clinical trial data for pimavanserin in PDP.
  • Analysis of treatment outcomes, focusing on psychosis symptoms and motor function.

Main Results:

  • Pimavanserin demonstrated significant reductions in hallucinations and delusions in PDP patients.
  • Treatment with pimavanserin did not worsen motor dysfunction.
  • Clinical trials suggest pimavanserin is a safe and effective treatment option.

Conclusions:

  • Pimavanserin shows promise as a safe and effective treatment for Parkinson's disease psychosis.
  • The drug addresses an unmet medical need, offering an alternative to traditional antipsychotics.
  • Further research is exploring pimavanserin for other psychiatric conditions.